VTRS

Viatris Inc (VTRS) Stock Price

Closed
VTRS
$19.85
-$0.37(-1.82%)

Content updated: 2026-11-20 18:14:36

Yesterday's Close
$20.22
Today's Open
$20.12
Today's High
$20.29
Today's Low
$19.66
Volume
7.24M shares
52-Week Range
$10.73-$21.50

As of 2026-11-20 18:14:36, Viatris Inc (VTRS) was quoted at $19.85, a change of -$0.37 (-1.82%) from the previous close. The day's range was $19.66–$20.29, and the 52-week range was $10.73–$21.50.

Why Is Viatris Inc (VTRS) Stock Falling?

AI Stock Price Analysis

Content updated: 2026-11-20 08:58:32

Viatris opened higher then weakened, with shares down 2.02% to $19.86 after fading from a $20.34 intraday high toward a $19.68 low, closing below volume-weighted average price (VWAP) on light volume. The company completed its acquisition of Pacira BioSciences this week.

Past 1W-4.51%Period Low $19.68Period High $20.99
Past 1M+6.54%Period Low $17.86Period High $21.19
Past 3M+22.21%Period Low $16.12Period High $21.19
Past 1Y+89.50%Period Low $10.15Period High $21.19

About Viatris Inc (VTRS)

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Ticker / Exchanges
VTRS / NASDAQ
Industry / Sector
Drug Manufacturers - Specialty & Generic / Healthcare
CEO
Scott Andrew Smith
Headquarters
Canonsburg,PA,US
Official Website
https://www.viatris.com
Listing Date
1980-03-17

Recent Company Events

  • 2027-02-25
    Earnings Report · ExpectedOn 2027-02-25, the 2026/Q4 earnings report is expected to be released.

Viatris Inc (VTRS) Derivatives Trading

VTRSTrade
Stocks

Trade U.S., Hong Kong, Japanese, and South Korean stocks directly. Selected U.S., Hong Kong, and South Korean stocks support 24/7 trading. You hold actual shares. Corporate actions such as dividends and stock splits are handled according to market rules.

VTRSTrade
CFD

Trade stock price movements through CFDs without holding the underlying shares. CFDs support long and short positions and leveraged trading. Be aware of spreads, trading fees, overnight fees, and liquidation risk.

Viatris Inc (VTRS) Company Financials

Valuation and Shares

Market Cap
$22.76B
P/E Ratio (TTM)
-37.50
P/B Ratio
1.66
Shares Outstanding
1.14B shares
Float Shares
1.13B shares
Dividend Yield (TTM)
2.41%

Latest Reported Financials

2026 Q3 Financials

Report Release Date: 2026-11-05

Operating Revenue (Actual)

$3.74B

Same Period Last Year: -0.28%

Earnings per Share (Actual)

$0.71

Same Period Last Year: +5.97%

Financials · Actuals

Actual Value2022/Annual2023/Annual2024/Annual2025/Annual
Revenue$16.26B$15.42B$14.73B$14.30B
Net Profit$2.07B$54.70M-$634.00M-$3.51B
Operating Cash Flow$2.99B$2.90B$2.30B$2.31B

VTRS FAQ

What is the current stock price of Viatris Inc (VTRS)?

x
As of 2026-11-20 18:14 (UTC+8), the latest available quote for Viatris Inc (VTRS) is $19.85 USD, with a change of -$0.37 USD (-1.82%) from the previous trading day's close. Current market status: Closed.

Which exchange is VTRS listed on?

x

How has Viatris Inc stock performed over the past month?

x

What is the market cap of Viatris Inc?

x

What are Viatris Inc's latest financial results?

x

What factors may affect the stock price of Viatris Inc (VTRS)?

x

Other Trading Markets

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.